Ambrx
Mark Janis has a wealth of experience in finance and accounting, holding various leadership roles such as Vice President of Corporate Controller and Vice President of Accounting Operations and Financial Reporting at Ambrx. Mark has also worked as a President at OneCore Financial and a Director of Finance/CFO at Siliken USA. With a BBA in Accounting/Finance from Beedie School of Business at Simon Fraser University, Mark has a strong background in equity administration, tax provision, SEC filings, and SOX 404 compliance. Mark's expertise in the finance industry is evident through their work with companies like ImmunityBio, Inc., Visual Communications Company, LLC, Qualcomm, and SAIC.
Ambrx
Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties.